Status:
COMPLETED
Functional Implication of Corpus Callosum in Voluntary Strength in COPD Patients
Lead Sponsor:
5 Santé
Conditions:
Neurophysiology
Physiology
Eligibility:
All Genders
40-75 years
Phase:
NA
Brief Summary
Patients with COPD have lower capability of activating their muscles. At the cortical level, force production is not only controlled by contralateral primary motor cortex but also by ipsilateral motor...
Detailed Description
Chronic obstructive pulmonary disease (COPD) patients exhibit not only respiratory symptoms but also a peripheral muscular weakness. This weakness is characterized by a loss in strength, harmful for t...
Eligibility Criteria
Inclusion
- Health insurance
- Patients : COPD Gold II-IV
Exclusion
- Pregnant women
- Seizures
- Unable to give written consent
- Metalic object above shoulders
- Dermatological issue concerning surface electrodes
- Caffeine consumption \> 4 coffee / day
- Neurological disorders
- Opioid-based treatment
- Patients : recent exacerbation (\< 4 weeks)
- Patients : rehabilitation in previous 1 year
Key Trial Info
Start Date :
October 20 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 30 2019
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT03807258
Start Date
October 20 2018
End Date
March 30 2019
Last Update
January 13 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Cliniques du Souffle
Lodève, Herault, France, 34700
2
Cliniques du Souffle
Osséja, Pyrenees Orientales, France, 66340